US 12,491,182 B2
Polymorphs of triazole antifungal compound PC945
Christopher John Wallis, London (GB); Gerald Steele, Loughborough (GB); Suzanne Buttar, Cambridge (GB); Osama Suleiman, Cambridge (GB); Julian Northen, Sunderland (GB); John Mykytiuk, Sunderland (GB); and Jamie Marshall, Sunderland (GB)
Assigned to PULMOCIDE LIMITED, London (GB)
Appl. No. 17/782,232
Filed by Pulmocide Limited, London (GB)
PCT Filed Dec. 4, 2020, PCT No. PCT/GB2020/053107
§ 371(c)(1), (2) Date Jun. 3, 2022,
PCT Pub. No. WO2021/111142, PCT Pub. Date Jun. 10, 2021.
Claims priority of application No. 1917867 (GB), filed on Dec. 6, 2019.
Prior Publication US 2023/0028714 A1, Jan. 26, 2023
Int. Cl. A61K 31/496 (2006.01); A61K 31/7048 (2006.01); C07D 405/06 (2006.01)
CPC A61K 31/496 (2013.01) [A61K 31/7048 (2013.01); C07D 405/06 (2013.01)] 5 Claims
 
1. A compound of formula (I):

OG Complex Work Unit Chemistry
that is 4-(4-(4-(((3R,5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl) methoxy)-3-methylphenyl) piperazin-1-yl)-N-(4-fluorophenyl)benzamide in a crystalline form wherein the crystalline form is polymorphic Form 1 characterized by an X-ray powder diffraction pattern comprising characteristic peaks expressed in degrees 2-theta at ±0.2 of 7.0, 7.4, 7.9, 18.2, 19.7, 20.8, 24.7 degrees as measured using Cu Kα radiation or polymorphic Form 2 characterized by an X-ray powder diffraction pattern comprising characteristic peaks expressed in degrees 2-theta at ±0.2 of 10.8, 17.0, 20.3, 22.7, 23.9 and 24.3 degrees as measured using Cu Kα radiation.